Repros appoints Patrick Fourteau as chairman of the board
Mr. Fourteau is a seasoned pharmaceutical industry executive having over 35 years of healthcare industry experience, with particular expertise in executing sales strategies for pharmaceutical products, product acquisitions, out-licensing and mergers and acquisitions.
He is the President and CEO of New Haven Pharmaceuticals, Inc. He also serves as a member of the board of directors of Insys Therapeutics.
Mr. Fourteau's executive roles prior to joining New Haven Pharmaceuticals include President and CEO of Shionogi Pharma, Inc. (the US subsidiary of Shionogi & Co. Ltd. of Japan) from 2008 until 2010.
Immediately prior, he was President and CEO of Sciele Pharma, the publicly traded specialty pharmaceutical company, during the period when Shionogi acquired Sciele Pharma in 2008.
He has held additional executive roles at inVentiv Health, St. Jude Medical Inc. and 19 years as VP of Pharmaceutical Operations for Lilly International.
Mr. Fourteau earned an MBA from Harvard University and both a B.A. and M.A. in mathematics from The University of California, Berkeley. ■
LATEST MOVES FROM Texas
- Texas Instruments elects Brian Crutcher to board
- Integera appoints Joseph W. Dziedzic as permanent CEO
- ConocoPhillips appoints Sharmila Mulligan to board
- Summit Hotel Properties appoints Hope Taitz as independent director
- Commercial Metals appoints Barbara Smith as CEO
More inside POST